With 74028.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.21 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.94 whereas the lowest price it dropped to was $2.59. The 52-week range on ENTO shows that it touched its highest point at $5.84 and its lowest point at $0.97 during that stretch. It currently has a 1-year price target of $108.00. Beta for the stock currently stands at 1.17.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ENTO was down-trending over the past week, with a drop of -7.79%, but this was down by -28.10% over a month. Three-month performance surged to 32.09% while six-month performance rose 129.77%. The stock gained 52.20% in the past year, while it has gained 108.84% so far this year.
Float and Shares Shorts:
At present, 3.36 million ENTO shares are outstanding with a float of 3.12 million shares on hand for trading. On 2025-11-14, short shares totaled 16623.0, which was 77.99999999999999 higher than short shares on 1760486400. In addition to Mr. Jason David Sawyer as the firm’s CEO & Director, Ms. Anna Skowron serves as its Interim Chief Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. The EBITDA in the recently reported quarter was -$934787.0 and diluted EPS was -$0.75.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.39 being high and -$3.39 being low. For ENTO, this leads to a yearly average estimate of -$3.39.
